BHCM
FATE icon

Brevan Howard Capital Management’s Fate Therapeutics FATE Stock Holding History

Brevan Howard Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-24,636
Closed -$40.6K – 1260
2024
Q4 		$40.6K Buy
+24,636
New +$62.1K ﹤0.01% 989
2024
Q3 		– Sell
-24,223
Closed -$79.5K – 1240
2024
Q2 		$79.5K Buy
+24,223
New +$106K 0.01% 984
2024
Q1 		– Sell
-38,230
Closed -$143K – 1110
2023
Q4 		$143K Buy
38,230
+20,893
+121% +$49.3K 0.01% 921
2023
Q3 		$36.8K Buy
+17,337
New +$57.4K 0.01% 371

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $12.3B AUM 37.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.47T AUM 27.86% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return